*) will the DSMB report in early October only be a YES or NO according to the Phase III ZoptEC trial or will it also tell more details about efficacy?
It will mostly be a simple recommendation. Not much data will be released. We will not have access to the data, only the DSMB will.
*) is it somehow to be interpreted negatively that the interim analysis is earlier than originally planned (Oct vs. Dec)?
No. Completion of patient recruitment ahead of time is an element of explanation.
*) is there any forecast how much and how long the outstanding B warrants will move on to destroy shareholders value (like mine) in the ongoing dilution process (I´ve never seen before in my entire investors life)?
In disclosing our Q2 results on August 13, our CEO stated the following without giving a specific timeline: During the first quarter of this year, we made the decision to raise a significant amount of capital to see us through the next 18 months of the implementation of our strategy. As a result, we are in a strong financial position with cash and cash equivalents of approximately $45.5 million as of June 30. However, the pressure being exerted on our stock price since our public offering does not reflect this strong cash position, our recent achievements and overall corporate value. We believe that the dilution attributable to warrants issued in the offering during the first quarter is the reason for the pressure on our stock price and that such dilution could continue for the next several months. Nonetheless, we remain focused on our upcoming drug development and commercial milestones which we believe will enable us to ultimately achieve our goal of becoming a commercially operating specialty
biopharmaceutical company.
*) is the delisting from Nasdaq a szenario you think will be avoidable looking at the current share prize? (and if not - szenario B would meant Toronto or OTC as main trading platform?)
We cannot speculate at this time on the future stock price. We did say during our Annual Shareholder Meeting in May, that a reverse split would be possible, but only as a last resort measure. We will keep investors informed as soon as a decision will have been taken. Yes we would stay listed on TSX and could move to OTCBB. As for NASDAQ, should we not be compliant by December 14, 2015, we may appeal NASDAQ staff's determination to a Hearings Panel.
*) do you really think, the current cash position will last until the final results of ZoptEC end of next year?
Budgets are reviewed on a regular basis, making adjustments according to developments. As stated in our August 13, 2015 MD&A:
Based on our assessment, which took into account current cash levels, as well as our strategic plan and corresponding budgets and forecasts, we believe that we have sufficient liquidity and financial resources to fund planned expenditures and other
working capital needs for at least, but not limited to, the 12-month period following the statement of financial position date of June 30, 2015. We may endeavour to secure additional financing, as required, through strategic alliance arrangements or through other activities, as well as via the issuance of new share capital or other securities.